o Prostanoids/prostacyclin therapies (oral and inhaled) o Inhaled agents: Ventavis, Tyvaso Page 1 of 5 Revised 02/17/17
|
|
- Rachel Sims
- 6 years ago
- Views:
Transcription
1 Request fr Prir Authrizatin Pulmnary Arterial Hypertensin (PAH) Agents (Oral and Inhaled) Website Frm Submit request via: Fax All requests fr Pulmnary Arterial Hypertensin (PAH) agents (Oral and Inhaled) require prir authrizatin and will be screened fr medical necessity and apprpriateness using the criteria listed belw. Requests fr a nn-preferred agent will require dcumented failure r cntraindicatin f a preferred agent within the same class, unless specified therwise. PAH agents (Oral and Inhaled) Initial Prir Authrizatin Criteria Cverage will be prvided when the diagnsis is Pulmnary Arterial Hypertensin (PAH) WHO Grup I and all f the crrespnding criteria are met in sectins A, B, and C: A. Diagnsis Criteria Treatment is prescribed by, r in cnsultatin with, a cardilgist r pulmnlgist; AND Member has a diagnsis f PAH WHO Grup I (refer belw t Appendix I) cnfirmed by chart dcumentatin f right-heart catheterizatin (RHC) r echcardigraphy if the prvider indicates RHC is nt recmmended; AND Member has functinal class II, III r IV symptms (refer belw t Appendix II); AND Prceed belw t Sectin B. Treatment Criteria B. Treatment Criteria Endthelin receptr-antagnists (ERA): Letairis, Tracleer, Opsumit If the request is fr a nn-preferred ERA, must have dcumentatin f inadequate respnse, cntraindicatin r intlerance t a preferred agent within this class; AND Prceed belw t Sectin C. Planned PAH Treatment Regimen Phsphdiesterase type 5 inhibitrs (PDE-5 inhibitrs): sildenafil, Adcirca, Revati Member is nt cncurrently using nitrates (regularly r intermittently) r a guanylate cyclase stimulatr (e.g. Adempas [riciguat]); AND If the request is fr Revati tablets r Adcirca**, must have dcumentatin f inadequate respnse, cntraindicatin r intlerance t a preferred agent within this class **If Adcirca is requested with Letairis as initial cmbinatin therapy, this requirement des nt apply. OR If the request is fr Revati suspensin, must prvide clinical ratinale fr why member is unable t take a slid dsage frm (e.g. tablet) AND Prceed belw t Sectin C. Planned PAH Treatment Regimen Sluble Guanylate Cyclase Stimulatr: Adempas Member is nt cncurrently using nitrates (regularly r intermittently) r phsphdiesterase inhibitrs; AND Must have dcumentatin f inadequate respnse, cntraindicatin r intlerance t a PDE-5 inhibitr (e.g. sildenafil, Revati, Adcirca) AND Prceed belw t Sectin C. Planned PAH Treatment Regimen Prstanids/prstacyclin therapies (ral and inhaled) Inhaled agents: Ventavis, Tyvas Page 1 f 5
2 Must have dcumentatin f inadequate respnse, cntraindicatin r intlerance t at least ne ral therapy frm ne f the fllwing three therapeutic classes: a PDE-5 inhibitr (e.g. sildenafil, Adcirca r Revati), an ERA (e.g. Letairis, Opsumit, Tracleer), r a guanylate cyclase stimulatr (e.g. Adempas) OR dcumentatin the member has previusly received an infused prstacyclin therapy (e.g. epprstenl, Fllan, Veletri, Remdulin); AND If the request is fr a nn-preferred inhaled agent, must have dcumentatin f inadequate respnse, cntraindicatin r intlerance t a preferred agent within this class; AND Prceed belw t Sectin C. Planned PAH Treatment Regimen Oral agents: Uptravi, Orenitram ER Fr Uptravi: Must have dcumentatin f inadequate respnse, cntraindicatin r intlerance t at least ne ral therapy frm ne f the fllwing three therapeutic classes: a PDE-5 inhibitr (e.g. sildenafil, Adcirca, Revati), an ERA (e.g. Letairis, Opsumit, Tracleer), r a guanylate cyclase stimulatr (e.g. Adempas); AND Member is nt taking Uptravi in cmbinatin with a prstanid/prstacyclin therapy (e.g. epprstenl, ilprst, treprstinil); AND Prceed belw t Sectin C. Planned PAH Treatment Regimen Fr Orenitram ER: Must have dcumentatin f inadequate respnse, cntraindicatin r intlerance t at least ne ral therapy frm ne f the fllwing three therapeutic classes: a PDE-5 inhibitr (e.g. sildenafil, Adcirca, Revati), an ERA (e.g. Letairis, Opsumit, Tracleer), r a guanylate cyclase stimulatr (e.g. Adempas); AND Member is nt taking Orenitram ER in cmbinatin with a prstanid/prstacyclin therapy (e.g. epprstenl, ilprst, treprstinil); AND Prceed belw t Sectin C. Planned PAH Treatment Regimen C. Planned PAH Treatment Regimen The requested drug will be used as mntherapy; OR Letairis and Adcirca are requested as initial cmbinatin therapy; OR If the requested drug will be used fr add-n therapy t existing mntherapy r dual therapy, then bth f the fllwing requirements must be met: i. Medicatins are frm different therapeutic classes; AND ii. Member has unrespnsive r prgressive disease despite established PAH-specific therapies Cverage will be prvided when the diagnsis is Chrnic Thrmbemblic Pulmnary Hypertensin (CTEPH) (WHO Grup 4) and all f the fllwing criteria are met: Fr Adempas: Treatment is prescribed by, r in cnsultatin with, a cardilgist r pulmnlgist; AND Member has a cnfirmed diagnsis f persistent/recurrent CTEPH after surgical treatment (i.e. pulmnary endarterectmy) r inperable CTEPH; AND Member is nt cncurrently using nitrates (regularly r intermittently) r phsphdiesterase inhibitrs If member is new t the plan and requests a cntinuatin f therapy, all f the fllwing criteria must be met: Chart dcumentatin indicates member is currently n requested therapy; AND Dcumentatin frm prescriber substantiates a diagnsis f PAH WHO Grup I r CTEPH (depending n agent requested); AND Treatment is prescribed by, r in cnsultatin with, a cardilgist r pulmnlgist Page 2 f 5
3 The requested dse is within FDA-apprved dsing recmmendatins. If a requested dse is abve these recmmendatins, medical ratinale must be submitted. Initial apprval duratin will be fr 3 mnths. Reauthrizatin Criteria Must prvide dcumentatin that demnstrates member is tlerating and receiving clinical benefit frm treatment Fr Revati Suspensin: must indicate that member remains unable t take a slid dsage frm (e.g. tablet) Reauthrizatin duratin will be fr 12 mnths Cverage may be prvided fr any nn-fda labeled indicatin if it is determined that the use is a medically accepted indicatin supprted by natinally recgnized pharmacy cmpendia r peer-reviewed medical literature fr treatment f the diagnsis(es) fr which it is prescribed. These requests will be reviewed n a case by case basis t determine medical necessity. Appendix 1: Wrld Health Organizatin (WHO) Clinical Classificatin f Pulmnary Hypertensin (PH) Grup 1 Pulmnary Arterial Hypertensin (PAH) Idipathic Heritable Drug/txin-induced Assciated with: Cnnective tissue disease HIV infectin Prtal hypertensin Cngenital heart disease Schistsmiasis Grup 1 Pulmnary ven-cclusive disease (PVOD) and/r pulmnary capillary hemangimatsis (PCH) Grup 1 Persistent pulmnary hypertensin f the newbrn (PPHN) Grup 2 PH due t left heart disease Grup 3 PH due t lung diseases and/r hypxia Grup 4 Chrnic thrmbemblic PH (CTEPH)and ther pulmnary artery bstructins Grup 5 PH with unclear and/r multifactrial mechanisms Appendix 2: Wrld Health Organizatin (WHO) Functinal Classificatin f Members with PH Classificatin Physical Activity Symptms (Dyspnea, fatigue, chest pain, syncpe) Class I N limitatin Nne upn rdinary physical activity Class II Slight limitatin Symptms appear upn rdinary physical activity Class III Marked limitatin Symptms appear upn less than rdinary activity Class IV Severe limitatin Symptms appear upn any physical activity r may even be present at rest; signs f right heart failure present References 1.) Taichman DB, Ornelas J, Chung L, et al. Pharmaclgic therapy fr pulmnary arterial hypertensin in adults: CHEST guideline and expert panel reprt. Chest. 2014; 146(2): Available at: Accessed March 29, Page 3 f 5
4 2.) Galie N, Humbert M, Vachiery JL, et al ESC/ERS Guidelines fr the diagnsis and treatment f pulmnary hypertensin. The Jint Task Frce fr the Diagnsis and Treatment f Pulmnary Hypertensin f the Eurpean Sciety f Cardilgy (ESC) and the Eurpean Respiratry Sciety (ERS). Eur Heart J. 2016:37(1): Available at: Accessed March 29, ) Uptravi [package insert]. Suth San Francisc, CA: Actelin Pharmaceuticals US, Inc.; Dec ) Sitbn O, Channick R, Chin KM, et al. Selexipag fr the treatment f pulmnary arterial hypertensin. N Engl J Med. 2015;373(26): ) Letairis [package insert]. Fster City, CA: Gilead Sciences, Inc.; Oct ) Tracleer [package insert]. Suth San Francisc, CA: Actelin Pharmaceuticals US, Inc.; Dec ) Opsumit [package insert]. Suth San Francisc, CA: Actelin Pharmaceuticals US, Inc.; Feb ) Revati [package insert]. New Yrk, NY: Pfizer Labs; May ) Adcirca [package insert]. Indianaplis, IN: Eli Lilly and Cmpany; Apr ) Ventavis [package insert]. Actelin Pharmaceuticals US, Inc.; Nv ) Tyvas [package insert]. Research Triangle Park, NC: United Therapeutics Crp.; Aug ) Orenitram ER [package insert]. Research Triangle Park, NC: United Therapeutics Crp.; Jan ) Sildenafil citrate. In: Micrmedex Slutins. US, Canada, UK: Truven Health Analytics Inc. Accessed 4/6/16. Page 4 f 5
5 Pulmnary Arterial Hypertensin (PAH) Agents (Oral and Inhaled) PRIOR AUTHORIZATION FORM Please cmplete and fax all requested infrmatin belw including any prgress ntes, labratry test results, r chart dcumentatin as applicable t Health Optins Pharmacy Services. FAX: If needed, yu may call t speak t a Pharmacy Services Representative. PHONE: Requesting Physician: Physician Specialty: Office Address: Patient Name: Health Optins ID: PROVIDER INFORMATION NPI: Office Cntact: Office Phne: Office Fax: MEMBER INFORMATION DOB: DRUG INFORMATION Medicatin: Strength: Frequency: Duratin: Is the member currently receiving requested medicatin? Yes N Date Medicatin Initiated: MEDICAL HISTORY Diagnsis: Has chart dcumentatin f right-heart catheterizatin r echcardigraphy been prvided cnfirming the diagnsis f pulmnary arterial hypertensin? Yes N Please select the Wrld Health Organizatin (WHO) Classificatin f Pulmnary Hypertensin: Grup 1 Grup 2 Grup 3 Grup 4 Grup 5 Please indicate WHO functinal class symptms: Class I Class II Class III Class IV Is the member currently taking a nitrate prduct? Yes N Will the requested medicatin be used as mntherapy r cmbinatin therapy? If cmbinatin therapy, please list ther drug(s): Mntherapy Cmbinatin Drug Name Strength & Frequency Ratinale fr additinal therapy If the request is fr Adempas (riciguat) fr a diagnsis f Chrnic Thrmbemblic Pulmnary Hypertensin (CTEPH) (WHO Grup 4), please answer the fllwing questins: Has the member previusly failed surgical treatment (such as pulmnary endarterectmy)? Yes N Des the member have inperable CTEPH? Yes N PREVIOUS THERAPY Status (Discntinued & Drug Name Strength/Frequency Dates f Therapy Why r Current) REAUTHORIZATION Has the member tlerated and received clinical benefit frm treatment? Yes N Please explain: ADDITIONAL SUPPORTING INFORMATION r CLINICAL RATIONALE Prescribing Physician Signature Date Page 5 f 5
Drug Therapy Guidelines
Applicable Medical Benefit x Effective: 1/1/18 Pharmacy- Frmulary 1 x Next Review: 12/18 Pharmacy- Frmulary 2 x Date f Origin: 5/28/06 Pulmnary Arterial Hypertensin : Revati (sildenafil), Ventavis (ilprst),
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2020-10 Program Prior Authorization/Medical Necessity PAH Agents Medication Adcirca (tadalafil), Adempas (riociguat), Letairis
More informationDrug Class Monograph. Policy/Criteria:
Drug Class Monograph Class: Pulmonary Arterial Hypertension Agents Drugs: Adcirca (tadalafil), Adempas (riociguat), Flolan (epoprostenol), Letairis (ambrisentan), Opsumit (macitentan), Orenitram (treprostinil),
More informationPulmonary Arterial Hypertension Drug Prior Authorization Protocol
Pulmonary Arterial Hypertension Drug Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationRituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Rituxan (rituximab) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Effective Date: 10/01/2015 POLICY A. INDICATIONS The indicatins belw including FDA-apprved indicatins and cmpendial uses
More informationFolotyn (pralatrexate)
Fltyn (pralatrexate) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/2018TBD03/01/2017 POLICY A. INDICATIONS The indicatins
More informationPULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Adcirca tadalafil Calendar Year Adempas riociguat Calendar Year Flolan epoprostenol sodium Calendar
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745
Generic Brand HICL GCN Exceptin/Other NALTREXONE CONTRAVE ER 41389 /BUPROPION LORCASERIN BELVIQ 34733 PHENTERMINE PHENTERMINE 20691 20692 20693 20713 PHENTERMINE LOMAIRA 20715 PHENTERMINE/TO PIRAMATE GUIDELINES
More informationRequest for Prior Authorization for Click here to enter text. Website Form Submit request via: Fax
Request fr Prir Authrizatin fr Click here t enter text. Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 Updated: 05/2018 DMMA Apprved: 05/2018 All requests fr Intravenus
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.10 Subject: Uptravi Page: 1 of 6 Last Review Date: September 15, 2017 Uptravi Description Uptravi
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.23 Subject: Sildenafil Citrate Powder Page: 1 of 6 Last Review Date: September 15, 2017 Sildenafil
More information1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.15 Subject: Flolan Veletri Page: 1 of 5 Last Review Date: September 15, 2017 Flolan Veletri Description
More informationSolid Organ Transplant Benefits to Change for Texas Medicaid
Slid Organ Transplant Benefits t Change fr Texas Medicaid Infrmatin psted February 13, 2015 Nte: All new and updated prcedure cdes and their assciated reimbursement rates are prpsed benefits pending a
More informationDrug Therapy Guidelines
Applicable Medical Benefit x Effective: 5/1/18 Pharmacy- Frmulary 1 x Next Review: 3/18 Pharmacy- Frmulary 2 x Date f Origin: 4/99 Gnadtrpin-Releasing Hrmne Agnists- Eligard, Luprn, Luprn-Dept, Luprn Dept-Ped,
More informationPharmacy Management Drug Policy
SUBJECT: Pulmonary Arterial Hypertension (PAH) POLICY NUMBER: Pharmacy-42 Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationClinical Policy: Macitentan (Opsumit) Reference Number: ERX.SPMN.88
Clinical Policy: (Opsumit) Reference Number: ERX.SPMN.88 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Luisiana Healthcare Cnnectins Prviders Questin GENERAL Why did Luisiana Healthcare Cnnectins implement a Medical Prgram? Answer
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Orencia (abatacept) Applicable Medical Benefit x Effective: 2/21/18 Pharmacy- Frmulary 1 x Next Review: 12/18 Pharmacy- Frmulary 2 x Date f Origin: 11/28/06 Pharmacy- Frmulary 3/Exclusive
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)
Questin GENERAL Why did MHS implement a Medical Specialty Slutins Prgram? Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Managed Health Services (MHS) Answer Effective Nvember
More informationClinical Policy: Treprostinil (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date:
Clinical Policy: (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date: 07.01.16 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important
More information2017 Optum, Inc. All rights reserved BH1124_112017
1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases
More informationHeart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or
Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): Angitensin
More informationOpioid Analgesics PA Request Provider Checklist
WVP Health Authrity Updated 05-12-2015 Opiid Analgesics PA Request Prvider Checklist *** If pssible, please include the fllwing infrmatin with PA requests fr piid analgesics. Including the requested infrmatin
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationNew Exception Status Benefits
FEBRUARY 2019 Nva Sctia Frmulary Updates New Exceptin Status Benefits Prcysbi (cysteamine bitartrate) Nucala (meplizumab) Ocaliva (betichlic acid) Ravicti (glycerl phenylbutyrate) Taltz (ixekizumab) Criteria
More informationClinical Policy: Treprostinil (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date:
Clinical Policy: (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date: 07.01.16 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQ s) Fr PA Health & Wellness Prviders Questin GENERAL Why is PA Health & Wellness implementing a Medical Specialty Slutins Prgram? Answer
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.21 Subject: Orenitram Page: 1 of 6 Last Review Date: June 24, 2016 Orenitram Description Orenitram
More informationAnnex III. Amendments to relevant sections of the Product Information
Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t
More informationHeart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or
Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): EMeasure
More informationPROVIDER ALERT. Comprehensive Diagnostic Evaluation (CDE) Guidelines to Access the Applied Behavior Analysis (ABA) Benefit.
Cmprehensive Diagnstic Evaluatin (CDE) Guidelines t Access the Applied Behavir Analysis (ABA) Benefit May 5, 2017 Clinical infrmatin that utlines medical necessity is required t supprt the need fr initial
More informationNIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO
NIA Magellan 1 Spine Care Prgram Interventinal Pain Management Frequently Asked Questins (FAQs) Fr Medicare Advantage HMO and PPO Questin GENERAL Why is Flrida Blue implementing a Spine Management prgram
More informationOral Therapies for Pulmonary Arterial Hypertension
Oral Therapies for Pulmonary Arterial Hypertension Leslie Wooten, PharmD PGY2 Internal Medicine Pharmacy Resident University of Cincinnati Medical Center April 30 th, 2018 Objectives Pharmacist Objectives
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.13 Section: Prescription Drugs Effective Date: July 1 2016 Subject: Tyvaso Page: 1 of 4 Last Review
More informationCLINICAL MEDICAL POLICY
Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019
More informationMylotarg (gemtuzumab ozogamicin) (Intravenous)
Myltarg (gemtuzumab zgamicin) (Intravenus) Last Review Date: 09/19/2017 Date f Origin: 09/19/2017 Dates Reviewed: 09/2017 Dcument Number: IC-0320 I. Length f Authrizatin Newly-Diagnsed AML De nv disease
More informationDrug Therapy Guidelines
Applicable* Medical Benefit x Effective: 2/15/19 Pharmacy- Frmulary 1 Next Review: 12/19 Pharmacy- Frmulary 2 Date f Origin: 4/1/05 Pharmacy- Frmulary 3/Exclusive Review Dates: 4/1/05, 2/1/06, 10/15/06,
More informationClinical Policy: Ambrisentan (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16
Clinical Policy: (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16 Last Review Date: 06/16 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationWound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018
Wund Care Equipment and Supply Benefits t Change fr Texas Medicaid July 1, 2018 Infrmatin psted May 11, 2018 Nte: Texas Medicaid managed care rganizatins (MCOs) must prvide all medically necessary, Medicaid-cvered
More informationBariatric Surgery FAQs for Employees in the GRMC Group Health Plan
Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 4/19/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More informationKadcyla (ado-trastuzumab emtansine) Document Number: IC-0092
Kadcyla (ad-trastuzumab emtansine) Dcument Number: IC-0092 Last Review Date: 2/6/2018 Date f Origin: 05/16/2013 Dates Reviewed: 7/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014, 5/2015, 8/2015,
More informationClinical Policy: Vedolizumab (Entyvio) Reference Number: ERX.SPA.163 Effective Date:
Clinical Plicy: Vedlizumab (Entyvi) Reference Number: ERX.SPA.163 Effective Date: 10.01.16 Last Review Date: 11.18 Revisin Lg See Imprtant Reminder at the end f this plicy fr imprtant regulatry and legal
More informationCRITERIA FOR USE: Requires Prior Authorization by Medical Director or Designee
What s New Medical Pharmaceutical Plicy September Updates 2017 MBP 154.0 Radicava (edaravne)- New Plicy CRITERIA FOR USE: Requires Prir Authrizatin by Medical Directr r Designee Radicava (edaravne) will
More informationPharmacy Prior Authorization Growth Hormone- Clinical Guidelines. Serostim Zorbtive somatropin
Pharmacy Prir Authrizatin Grwth Hrmne- Clinical Guidelines Gentrpin Humatrpe Nrditrpin Nutrpin Omnitrpe Saizen Serstim Zmactn Zrbtive smatrpin General Criteria fr Apprval: Omnitrpe vial frmulatin is the
More informationPrior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
Pharmacy Medical Necessity Guidelines: Effective: July 11, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Adcirca) Reference Number: HIM.PA.SP23 Effective Date: 05/17 Last Review Date: Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder at
More informationPharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications
Pharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications Effective: January 15, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
More informationActelion Presents REPAIR Study Interim Analysis at the American College of Cardiology's 68th Annual Scientific Session
Interim Analysis Shwed Treatment with OPSUMIT (macitentan) Assciated with Significant Imprvement in Right Ventricular (RV) Functin and Pulmnary Vascular Resistance (PVR) in Patients with Pulmnary Arterial
More informationCSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009
CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More informationXX Abraxane 100 MG SUSR (CELGENE CORP)
Plicy Medical Plicy Manual Apprved: D Nt Implement Until 1/31/19 Paclitaxel (Prtein-Bund) NDC CODE(S) 68817-0134-XX Abraxane 100 MG SUSR (CELGENE CORP) DESCRIPTION Paclitaxel is a natural prduct with antitumr
More informationOriginal Policy Date 12:2013
MP 5.01.18 Xlair (Omalizumab) Medical Plicy Sectin Prescriptin Drugs Issu12:2013e 4:2006 Original Plicy Date 12:2013 Last Review Status/Date Lcal plicy/12:2013 Return t Medical Plicy Index Disclaimer Our
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other SELEXIPAG UPTRAVI 42922 TREPROSTINIL ORENITRAM ER 40827 If the caller wishes to initiate a request then a MRF must be completed. This drug requires a written request
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.17 Subject: Remodulin Page: 1 of 5 Last Review Date: June 24, 2016 Remodulin Description Remodulin
More informationInjectable Agents for the Treatment of Pulmonary Arterial Hypertension (PAH)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Injectable Agents for the Treatment of Pulmonary Arterial Hypertension (PAH) Clinical Edit Information Included in this Document
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable* Hereditary Angiedema (HAE) Agents: Berinert (C1 esterase inhibitr [human]), Cinryze (C1 esterase inhibitr [human]), Haegarda (C1 esterase inhibitr [human]) Kalbitr (ecallantide),
More informationPerjeta (pertuzumab) Document Number: IC I. Length of Authorization. Dosing Limits. Initial Approval Criteria
Perjeta (pertuzumab) Last Review Date: 11/21/2017 Date f Origin: 11/01/2012 Dcument Number: IC-0096 Dates Reviewed: 12/2012, 3/2013, 6/2013, 9/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014, 3/2015,
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.16 Subject: Letairis Page: 1 of 6 Last Review Date: June 24, 2016 Letairis Description Letairis (ambrisentan)
More informationContinuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP
Cntinuus Psitive Airway Pressure (CPAP) and Respiratry Assist Devices (RADs), Including Bi-Level PAP Benefit Criteria t Change fr Texas Medicaid Effective March 1, 2017 Overview f Benefit Changes Benefit
More informationCardiac Rehabilitation Services
Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Adcirca) Reference Number: CP.PHAR.198 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More informationOrencia (abatacept) Document Number: MODA-0091
Orencia (abatacept) Dcument Number: MODA-0091 Last Review Date: 09/19/2017 Date f Origin: 07/02/2010 Dates Reviewed: 07/2010, 09/2010, 12/2010, 02/15/11, 03/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Letairis) Reference Number: CP.PHAR.190 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace, Medicaid Revision Log See Important Reminder at the
More informationWidening of funding restrictions for rituximab and eltrombopag
20 February 2014 Widening f funding restrictins fr rituximab and eltrmbpag PHARMAC is pleased t annunce the apprval f prpsals t widen the restrictin n rituximab use in DHB hspitals and expand the funding
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Tracleer Page: 1 of 6 Last Review Date: September 15, 2017 Tracleer Description Tracleer (bosentan)
More informationADCIRCA (tadalafil) The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Intravenus Vancmycin Use in Adults Intermittent (Pulsed) Infusin Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Ambrisentan (Letairis) Reference Number: CP.PHAR.190 Effective Date: 07.01.18 Last Review Date: 01.12.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the
More informationDear Student, IMMUNIZATION RECORD INSTRUCTIONS
Dear Student, Welcme t the University f Chicag! The State f Illinis and University regulatins require students t prvide prf f required immunizatins prir t registratin fr classes. In rder t cmplete this
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
SILDENAFIL oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Letairis) Reference Number: CP.PHAR.190 Effective Date: 03.16 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationHigh Performance Network Quality Criteria for Designation
Selected quality measures include: Specialty Measure Descriptin Allergy / Immunlgy Asthma Drug Mgt Vaccine Pneumnia Vaccine High Perfrmance Netwrk Quality Criteria fr Designatin AvMed has selected certain
More informationAPPENDIX A Certification of Advanced Disease:
APPENDIX A Certificatin f Advanced Disease: Name: DOB: Member ID: Name f Palliative Care Prgram: A. General Criteria: Check each f the fllwing that apply (All needed fr eligibility). Patient wh is likely
More informationXX Abraxane 100 MG SUSR (CELGENE CORP
Medical Manual Apprved Revised: D Nt Implement until 6/30/2019 Paclitaxel (Prtein-Bund) NDC CODE(S) 68817-0134-XX Abraxane 100 MG SUSR (CELGENE CORP DESCRIPTION Paclitaxel is a natural prduct with antitumr
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Flolan, Veletri) Reference Number: CP.PHAR.192 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder
More informationObesity/Morbid Obesity/BMI
Obesity/mrbid besity/bdy mass index (adult) Obesity/Mrbid Obesity/BMI Definitins and backgrund Diagnsis cde assignment is based n the prvider s clinical judgment and crrespnding medical recrd dcumentatin
More informationTREPROSTINIL Generic Brand HICL GCN Exception/Other TREPROSTINIL REMODULIN 23650
Generic Brand HICL GCN Exception/Other TREPROSTINIL REMODULIN 23650 SODIUM TREPROSTINIL TYVASO 36537 36539 36541 TREPROSTINIL ORENITRAM 40827 **Please use the criteria for the specific drug requested**
More informationClinical Policy: Deutetrabenazine (Austedo) Reference Number: ERX.SPA.150 Effective Date:
Clinical Plicy: (Austed) Reference Number: ERX.SPA.150 Effective Date: 09.01.17 Last Review Date: 05.18 Revisin Lg See Imprtant Reminder at the end f this plicy fr imprtant regulatry and legal infrmatin.
More informationHIP REPLACEMENT SURGERY (ARTHROPLASTY)
Prtcl: ORT015 Effective Date: June 1, 2017 HIP REPLACEMENT SURGERY (ARTHROPLASTY) Table f Cntents Page COMMERCIAL & MEDICAID COVERAGE RATIONALE... 1 MEDICARE COVERAGE RATIONALE... 3 U.S.FOOD AND DRUG ADMINISTRATION
More informationMeasure Information Form
Release Ntes: Measure Infrmatin Frm Versin 2.0 **NQF-ENDORSED VOLUNTRY CONSENSUS STNDRDS FOR HOSPITL CRE** Measure Set: Heart Failure (HF) Set Measure ID#: Measure Infrmatin Frm Perfrmance Measure Name:
More informationOntario s Referral and Listing Criteria for Adult Lung Transplantation
Ontari s Referral and Listing Criteria fr Adult Lung Transplantatin Versin 2.0 Trillium Gift f Life Netwrk Adult Lung Transplantatin Referral & Listing Criteria PATIENT REFERRAL CRITERIA: The patient referral
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Opsumit) Reference Number: CP.PHAR.194 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tracleer) Reference Number: CP.PHAR.191 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More information